PainResearch Phase

Leu-Enkephalin

Endogenous peptide

Overview

Leu-enkephalin is a pentapeptide (Tyr-Gly-Gly-Phe-Leu) that functions as an endogenous opioid agonist with preferential activity at delta-opioid receptors and moderate affinity for mu receptors. It is derived from the precursor proenkephalin and is widely distributed in the central and peripheral nervous systems.

Mechanism of Action

The peptide modulates nociceptive transmission and contributes to endogenous analgesia. Leu-enkephalin is rapidly degraded by peptidases, limiting its duration of action..

Research Summary & Key Findings

Preclinical studies have demonstrated analgesic effects of leu-enkephalin in rodent pain models when administered centrally or when protected from enzymatic degradation. Clinical use of native leu-enkephalin has been precluded by its rapid metabolism and poor bioavailability. Research has focused on developing stabilized analogs and peptidase-resistant derivatives, though none have reached approval.

Clinical Status

Research Phase

Leu-Enkephalin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous peptide

Related Peptides in Pain

Find a Provider

Find a verified provider who offers Leu-Enkephalin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Leu-Enkephalin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.